Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

January 10, 2020

Study Completion Date

January 10, 2020

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).

Trial Locations (7)

115 27

Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology, Athens

124 62

"University General Hospital of Athens Attikon, B' University Pulmonary Clinic", Chaïdári

711 10

University General Hospital of Heraklio, Pulmonary Clinic, Heraklio

455 00

University General Hospital of Ioannina, Ioannina

413 34

General University Hospital of Larisa; Pneumonology Clinic, Larissa

570 10

General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept., Thessaloniki

Papanikolaou Hospital; Pneumonology Clinic, Thessaloniki

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03115619 - Quality of Life Study in Participants With IPF Under Pirfenidone Treatment | Biotech Hunter | Biotech Hunter